| Literature DB >> 33935964 |
Yongjie Liu1, Mengyang Du2, Yuexin Gan1, Shihua Bao2, Liping Feng1,3, Jun Zhang1.
Abstract
The underlying correlative mechanisms between Insulin resistance (IR) and recurrent pregnancy loss (RPL) in patients without polycystic ovarian syndrome (PCOS) remain inconclusive. To investigate the association between triglyceride (TG) levels, lymphocyte subsets, and IR in RPL patients without PCOS and obesity. Eighty-nine subjects with an unexplained RPL, independent of PCOS/obesity were enrolled in this study. A 75-g oral glucose tolerance test was performed on each subject with plasma tested for glucose and insulin. The fasting venous blood of all subjects was collected for routine clinical chemistry analysis. Lymphocyte subsets were analyzed by four-color flow cytometry. As a result, TG levels were significantly elevated in RPL patients with IR compared to those without IR. Pearson linear correlation model and receiver operating characteristic (ROC) curve analyses revealed a significant positive association between TG and HOMA-IR index value. In multiple logistic regression analysis, TG was significantly associated with the risk of hyperinsulinemia and increased CD3+CD4+/CD3+CD8+ ratio which was significantly negatively correlated with disposition index (DI30) and DI120, indicators for insulin sensitivity. In addition, DI30 and DI120 were significantly decreased in the higher CD3+CD4+/CD3+CD8+ group. Our findings showed that the elevated TG and altered immune responses in RPL patients with IR are independent of PCOS and obesity, and could be used as an indicator of IR in RPL patients. These results contribute to the understanding of the pathophysiology of IR in RPL for potential prevention and therapeutic targets.Entities:
Keywords: CD3+CD4+/CD3+CD8+ ratio; insulin resistance; insulin sensitivity; recurrent pregnancy loss; triglyceride
Mesh:
Substances:
Year: 2021 PMID: 33935964 PMCID: PMC8082681 DOI: 10.3389/fendo.2021.621845
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Figure 1Flow chart for the exclusion in this study.
Characteristics of participants in this study.
| Variables | Non-IR (n = 33) | IR (n = 56) |
|
|---|---|---|---|
| Age (years)a | 30.5 ± 4.8 | 30.6 ± 3.4 | 0.95 |
| Body mass index (BMI, kg/m2) | 20.9 ± 2.0 | 22.2 ± 2.6 | 0.009* |
| <18.5 | 6 (18) b | 5 (9) | 0.34 |
| 18.5 ≤ BMI < 24 | 24 (73) | 37 (66) | 0.68 |
| 24 ≤ BMI < 28 | 3 (9) | 14 (25) | 0.12 |
| Waist circumstance (cm) | 66.0 ± 2.2 | 65.9 ± 2.6 | 0.92 |
| Education | |||
| Illiterate | 0 (0) | 0 (0) | NEc |
| High school or lower | 7 (21) | 9 (16) | 0.75 |
| College | 23 (70) | 45 (80) | 0.38 |
| Postgraduate or higher | 3 (9) | 2 (4) | 0.54 |
| History of smoking | 0 (0) | 0 (0) | NE |
| History of drinking | 0 (0) | 0 (0) | NE |
| History of diabetes | 0 (0) | 2 (4) | 0.72 |
| History of hypertension | 0 (0) | 3 (5) | 0.46 |
| Virus | |||
| HIV+ | 0 (0) | 0 (0) | NE |
| HPV+ | 1 (3) | 0 (0) | 0.79 |
| Syphilis | 0 (0) | 0 (0) | NE |
| Antibody | |||
| Anticardiolipin antibody (IgA, IgM, IgG) | 0 (0) | 0 (0) | NE |
| Anti DNA antibody (single- and double- | 0 (0) | 0 (0) | NE |
| Anti ENA (extractable nuclear antigen, 7 | 0 (0) | 0 (0) | NE |
| Anti-beta 2 glycoprotein antibody (Ig, | 0 (0) | 0 (0) | NE |
| Irregular antibody | 0 (0) | 0 (0) | NE |
| Medical history | |||
| Endometriosis | 0 (0) | 0 (0) | NE |
| Uterine fibroids | 2 (6) | 0 (0) | 0.26 |
| Endometrial polyps | 0 (0) | 0 (0) | NE |
| Intrauterine adhesion | 2 (6) | 2 (4) | 0.99 |
| Ovarian cysts | 0 (0) | 0(0) | NE |
| Pelvic inflammation | 0 (0) | 0 (0) | NE |
a.Data are presented as mean ± SD. b.Data are presented as n (%). c.NE, not estimable (due to nullity of category in both groups). Pelvic inflammation means Pelvic Inflammatory Diseases, including endometritis, salpingitis, and chronic pelvic inflammation.
Comparison of β-cell function and insulin sensitivity, lipid profiles, and lymphocyte subsets of RPL patient with IR and non-IR.
| Non-IR (n = 33) | IR (n = 56) |
| ||
|---|---|---|---|---|
| β-cell function and insulin sensitivity | HOMA-IR | 1.3 ± 0.5 | 2.6 ± 1.5 | <0.0001* |
| HOMA-β | 92.5 ± 33.4 | 144.2 ± 69.2 | 0.0002* | |
| ΔI30/ΔG30 | 20.7 ± 18.1 | 21.6 ± 10.7 | 0.78 | |
| InsAUC30/GluAUC30 | 36.2 ± 16.8 | 46.6 ± 21.1 | 0.03* | |
| InsAUC120/GluAUC120 | 49.8 ± 21.0 | 67.4 ± 30.0 | 0.007* | |
| Matsuda index (ISIM) | 8.0 ± 3.0 | 4.9 ± 2.3 | <0.0001* | |
| DI | 75.7 ± 20.4 | 62.0 ± 20.1 | 0.005* | |
| DI30 | 261.0 ± 96.1 | 194.7 ± 72.7 | 0.0009* | |
| DI120 | 358.1 ± 117.2 | 275.8 ± 81.9 | 0.0005* | |
| Lipid profiles | TCH (mmol/L) | 4.4 ± 0.7 | 4.4 ± 0.9 | 0.97 |
| TG (mmol/L) | 0.8 ± 0.4 | 1.1 ± 0.6 | 0.025* | |
| LDL-C (mmol/L) | 2.8 ± 0.3 | 2.9 ± 0.4 | 0.35 | |
| HDL-C (mmol/L) | 1.3 ± 0.3 | 1.4 ± 0.4 | 0.17 | |
| HCY (µmol/L) | 9.5 ± 2.8 | 8.6 ± 2.3 | 0.20 | |
| TSH (mIU/L) | 1.8 ± 0.9 | 2.2 ± 1.0 | 0.11 | |
| FT3 (pmol/L) | 5.0 ± 0.4 | 5.0 ± 0.6 | 0.97 | |
| FT4 (pmol/L) | 16.2 ± 2.1 | 17.2 ± 2.3 | 0.12 | |
| Lymphocyte subsets | CD3+ cells (%) | 70.1 ± 9.7 | 67.6 ± 8.4 | 0.22 |
| CD3+CD4+ cells (%) | 36.1 ± 6.9 | 34.9 ± 6.4 | 0.43 | |
| CD3+CD8+ cells (%) | 28.1 ± 7.6 | 26.9 ± 6.0 | 0.39 | |
| CD3+CD4+/CD3+CD8+ cell Ratio | 1.4 ± 0.5 | 1.4 ± 0.4 | 0.89 | |
| CD16+CD56+ cells (%) | 16.6 ± 9.1 | 18.7 ± 8.5 | 0.27 | |
| CD19+ cells (%) | 11.2 ± 3.0 | 11.9 ± 3.8 | 0.76 |
IR, insulin resistance; non-IR, none insulin resistance; HOMA-IR, homeostasis model assessment for insulin resistance; HOMA-β, homeostasis model assessment of β cell function; DI, disposition index, representing an adjusted insulin sensitivity; TCH, total cholesterol, TG, triglyceride; LDL, low density lipoprotein-cholesterol; HDL, high density lipoprotein-cholesterol; HCY, homocysteine; TSH, thyrotropin; FT3, free triiodothyronin; and FT4, free thyroxine. *Significant difference between the two groups.
Figure 2Glucose and insulin levels between insulin resistance group (IR) and non-insulin resistance group (Non-IR).
Figure 3Correlation between TG levels and HOMA-IR or insulin sensitivity demonstrated using Pearson’s linear correlation model and ROC curve analysis. Association between TG and HOMA-IR (A), TG and DI (B), TG and DI30 (C), and TG and DI120 (D). ROC curve analysis for TGs and HOMA-IR (E), DI (F), and DI120 (G).TG, Triglyceride; HOMA-IR, homeostasis model assessment for insulin resistance; DI, disposition index, representing adjusted insulin sensitivity according to HOMA-IR.
Logistic regression analysis for hyperinsulinemia and CD3+CD4+/CD3+CD8+ ratio.
| Models | B | SE |
| OR (95% CI) | |
|---|---|---|---|---|---|
| Hyperinsulinemia | Model I | ||||
| TG levels | 1.02 | 0.46 | 0.02 | 2.78 (1.14 - 6.78) | |
| Model II | |||||
| TG levels | 1.02 | 0.46 | 0.03 | 2.77 (1.12 - 6.84) | |
| CD3+CD4+/CD3+CD8+ | Model I | ||||
| TG levels | 1.13 | 0.47 | 0.02 | 3.10 (1.24–7.72) | |
| Model II | |||||
| TG levels | 1.05 | 0.63 | 0.04 | 2.85 (0.83–9.77) |
Model I, variables were introduced into the logistic regression model; Model II, adjustment for confounding factors including age, and BMI. BMI, Body mass index; TG, triglyceride; B, regression coefficient; SE, standard error; OR, odds ratio; CI, confidence interval.
Figure 4Clinical implication of CD3+CD4+/CD3+CD8+ ratio in RPL patients with IR. (A) RPL women with decreased CD3+CD4+/CD3+CD8+ ratio had significantly higher levels of DI30 and DI120. The increase in the ratio of CD3+CD4+/CD3+CD8+ was marked associated with low (B) DI30 and (C) DI120 levels. ROC curve analysis for CD3+CD4+/CD3+CD8+ ratio and DI30 (D), and DI120 (E). Data is presented as mean ± standard deviation. DI, disposition index, representing adjusted insulin sensitivity according to HOMA-IR.